When analyzing gene profiles of 80 glioblastomas, CD133 emerged as a predictor for drug resistance and treatment outcome in patients treated with concurrent chemoradiotherapy (n = 42; p = 0.004) [103]. This evidence concerns the gene PROM1 and glioblastoma.